Navigation Links
Pegylated in Medical News

Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia

Companies Build on Existing Collaboration For Long Acting Blood Clotting Factors For Hemophilia SAN CARLOS, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced a new agreement with subsidiaries of Baxter International Inc. to d...

PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy

First and Only Peginterferon Therapy Approved for Retreating Both Hepatitis C Relapsers and Nonresponders KENILWORTH, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the European Commission on October 30 approved 48-week ...

Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)

...ission. ABOUT KRYSTEXXA (TM) KRYSTEXXA(TM) (pegloticase) is a pegylated uricase enzyme intended for the treatment of chronic gout in patients refra.... Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a pegylated uricase enzyme intended for the treatment of chronic gout in patients refra...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...t - Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart) II-1 Market Overview II-2 pegylated Alpha Interferon Plus Ribavirin - The Standard Therapy II-2 Approved Drugs for HCV Combination Therapy II-2 Table 2: HCV Treatment Market in t...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

...eening for Breast Cancer Susceptibility Gene (BRCA) deficiencies. Gynecological Cancers: Combination of carboplatin + pegylated liposomal doxorubicin will be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer For advanced cervical cancer, the combi...

Good news for some hard-to-treat hepatitis C patients

...including liver cancer and death. For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of pegylated interferon and ribavirin anti-viral therapy that may last from six months to a year. The remaining patients, known as non-responders, may improve ...

Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal

...ibavirin in Japan. Taribavirin, a prodrug of ribavirin, is in Phase II development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. "This agreement with Schering-Plough releases our company from the last right of refusal and provides us more flexibility to pursue...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

... (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. Study Design : Patients wi...

AGA Institute presents cutting-edge research during DDW

...at re-treated hepatitis C patients who had previously failed treatment with pegylated interferon and ribavirin (patients received treatment with telaprevir combined with pegylated interferon and ribavirin). Another abstract will present the results of...

New treatment option for patients with chronic hepatitis C

...alf of the American Association for the Study of Liver Diseases (AASLD). Nearly half of all HCV patients do not respond to the standard therapy of pegylated interferon and ribavirin. They remain at risk for developing life-threatening liver disease. So far, other alternative therapies have not been particu...
Pegylated in Medical Technology

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

- Systemic treatment with chemotherapy and pegylated enzyme produces significantly enhanced survival compared to chemotherapy alone - - Pegylated enzyme well tolerated - SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharma...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

EORTC 18991 Phase III Study Results Published in The Lancet KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sus...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

- New Approach to Targeting the Tumor Microenvironment - SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical ...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combined with an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from two phase IIb studies of the novel combination of valopicitabine (NM283) ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

-- EORTC 18991 Phase III Study Results Presented At ASCO -- CHICAGO – June 2, 2007 – Long-term treatment with pegylated interferon alfa-2b in stage III melanoma had a significant and sustained impact on relapse-free survival (RFS), according to the results of the largest adjuvant tri...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ing developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...f-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the current standard-of-care, pegylated interferon and ribavirin, to determine the optimal IDX184 doses to advance into broader clinical trials." In the 75 and 100 mg/day cohorts, ...

Telik Announces Presentation at ASCO Annual Meeting

...zed clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual me... "Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...ion site pain (<2%) and a low level of discontinuations due to adverse events (5%). About CIMZIA (R) CIMZIA (R) is the only pegylated anti-TNF (Tumour Necrosis Factor). Cimzia (R) has a high affinity for human TNF-alpha, selectively neutralising the pathophysiological effects of T...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

...ients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. (3) No safety and efficacy data are available for treatmen...
Pegylated in Biological News

Biolex presents Locteron US Phase 2a hepatitis C data at EASL

...ects, including flu-like symptoms, associated with pegylated interferons, the current standard of care. Biolex ...of Locteron, and to directly compare Locteron with pegylated interferon. Patients were randomized to receive ei...rofile and dosing convenience compared to existing pegylated interferon products. In contrast to Locteron's con...

Promising new treatment option for women with recurrent ovarian cancer

... Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to... after first-line therapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus tr...over 3 hours every 3 weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks...

American Chemical Society's Weekly PressPac -- Nov. 7, 2007

...ment, the researchers indicate. ARTICLE #1 FOR IMMEDIATE RELEASE "Conjugation to Increase Treatment Volume during Local Therapy: A Case Study with pegylated Camptothecin" DOWNLOAD PDF http://pubs.acs.org/cgi-bin/sample.cgi/bcches/asap/pdf/bc700214h.pdf DOWNLOAD HTML http://pubs.acs.org/cgi-bin/sa...

Clearance of hepatitis C viral infection after liver transplantation

...h interferon (IFN) and/or ribavirin before LT. Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, pegylated IFN, in the treatment before liver transplantation. PEGylation is a chemical modification incurring higher water-solubility and higher stability to th...

Novel therapy combinations gain ground in treating hepatitis

...ptidomimetic protease inhibitor, VX-950, has previously shown substantial anti-viral effects in combination with the frequently used hepatitis therapy pegylated interferon (pegIFN). In this study, researchers evaluated the safety and antiviral response of VX-950 in combination with pegIFN and ribavirin (RBV)....
Pegylated in Biological Technology

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in pla...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...ing developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...is being developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

...ys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the United States Food and Drug Administrati...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...d development of ANA598, in particular a Phase II study in combination with pegylated interferon-alpha and ribavirin. The restructuring included a reduction in...received FDA clearance for the Phase II study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. I...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

...Ph.D., chairman and chief executive officer of Idenix. "As we work through the second half of the year, we plan to evaluate IDX184 in combination with pegylated interferon and ribavirin in a 14-day dose-ranging study. Additionally, we plan to file investigational new drug applications from our non-nucleoside p...

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

...ory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic pegylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure g...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

...e (SVR), was achieved demonstrating that INFERGEN provides a second chance to those HCV patients failing to respond to standard, first-line therapy of pegylated interferon (PEG-IFN) plus ribavirin (RBV). "The retreatment of PEG-IFN/RBV nonresponders with INFERGEN and RBV is safe and efficacious and can be con...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

...being developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

...ng to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated interferon-alpha and ribavirin. As part of this restructuring, the Company intends to suspend further development of ANA773 and is reducing its...
Other Tags
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... Women’s Excellence is pleased to announce ... on their website. There are over 75 terms and phrases ... , “This gives our patients a better understanding of what ... they may not understand. With this resource, our patients are ... and find terms and phrases that they may not remember or ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured ... takes a look at the latest and coolest technology products ... NewsWatch and a technology expert, conducted the review and shared ... drinks. , According to Home Distillation of Alcohol, it's understood ... there’s a pretty cool product that’ll help anyone achieve a ...
(Date:2/28/2015)... Heart diseases are on the rise in India. ... population and 5 percent of rural adult population suffer ... of them require specialized investigation and treatment to prevent ... (CVD). , A division of Indian Business News Agency ... “Indian Coronary Stent Market Forecast to 2019”. The new ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ... 2020. Also, a seven-year historic analysis is provided for these markets. ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
Other Contents